Identification of a large homozygous SPG21 deletion in a Chinese patient with Mast syndrome

A 37‐year old man presented a slight delay in early developmental milestones, cognitive decline, difficulty walking, cerebellar signs and extrapyramidal signs. Brain magnetic resonance imaging (MRI) showed a thin corpus callosum, cerebral atrophy, non‐specific white‐matter hyperintensity, and cerebellar atrophy. The genetic test revealed a putative homozygous deletion in SPG21 from exon 3 through exon 7, which was further validated by long‐range primer‐walking PCR. This is the first report of Chinese patient with Mast syndrome carrying a large homozygous SPG21 deletion.


Identification of a large homozygous SPG21 deletion in a Chinese patient with Mast syndrome
Dear Editors, Mast syndrome (OMIM #248900) is an extremely rare autosomal recessive disease characterized by progressive hereditary spastic paraplegia (HSP), dementia, and other central nervous system symptoms. This disease was firstly described and occurred with high frequency in the Old Order Amish owing to an ancestral founder mutation in SPG21 gene. 1 SPG21 (also known as ACP33) was identified as the causative gene of Mast syndrome in 2003. 1 As the sole causative gene of Mast syndrome so far, there were only three variants in SPG21 reported. 2,3 In this study, we reported the first Chinese patient with Mast syndrome carrying a large homozygous SPG21 deletion.
The proband was a 37-year old man born at term after an uneventful pregnancy with no family history of neurologic disease. A slight delay in early developmental milestone was noted as he started walking at around 17 months. Also, learn difficulties, bradyphrasia, and gait dysfunction were noted during the childhood. At the age of 8, he started wearing eyeglasses owing to hyperopia. At the age of 34, the patient presented progressive slow reaction, dysarthria, unsteady walking, and declined mental function with executive dysfunction. Additionally, he occasionally showed fecal incontinence since the age of 36. Notably, his parents were in consanguineous marriages ( Figure 1A Table S1). Quantitative real-time PCR targeting SPG21 exon 8-9 region revealed unchanged mRNA expression in I-1 and II-4, compared with the normal familial member III-1 ( Figure S1). Therefore, this large deletion did not lead to nonsense-mediated mRNA decay but produced a putative protein lacking 204 amino acid residues (p. (Ile22_Val224del)).
Mast syndrome is a complicated form of HSP and was rarely reported worldwide. It is caused by mutations within SPG21 encoding a protein named "Maspardin," which contained a noncatalytic alpha/beta hydrolase fold domain and was involved in the negative regulation of CD4 activity via protein-protein interaction. 4 Within the interaction region, Ser109 is critical for the interaction of maspardin with CD4. In addition, maspardin could interact with Rab7 GTPase, which orchestrate vesicular trafficking, maturation, and fusion. 5 Although the specific mechanism was not clear, knockout of SPG21 resulted in hind limb dysfunction in mice and increasing axon branching in neurons. 6 Until now, only three variants in SPG21 have been documented. Among these reported variants, two variants producing frameshifts (p. Arg40Glufs*27 and p. Thr201Asnfs*13) cause generally identical symptoms. 1,3 However, the Japanese patients carrying the homozygous missense variant (p. Ala108Pro), which was next to the critical site of the alpha/beta hydrolase fold domain (Ser109), showed strikingly late-onset HSP symptoms without bulbar, extrapyramidal, or cerebellar signs. 2 The large deletion in SPG21 have not been reported before. In our study, the patient carrying large homozygous deletion of SPG21 shared the most symptoms with patients carrying SPG21 frameshift variants, but presented childhood-onset hyperopia and early-onset fecal incontinence. Hyperopia may be caused by other factors rather than carrier, also had hyperopia since childhood. We supposed his fecal incontinence might result from frontal involvement, which is consistent with the imaging findings. To uncover the genotypephenotype correlation, the accumulations of patients with SPG21 mutation are required. Recently, functional MRI (fMRI) has been performed in various central nervous system disease and revealed altered functional connectivity in different brain areas. 7,8 Conventional brain MRI usually reveals the structure alterations in complicated HSP, while fMRI could detect the alterations of the brain activities in both pure and complicated HSP, which emphasize the need for combined analysis of fMRI and structure MRI at multiple scales in Mast syndrome patients. 9,10 In addition, we also found this large deletion did not influence the level of SPG21 mRNA, indicating the disappearance of the allele mainly causes the dysfunction of corresponding protein. Due to the technical and material limitations, we did not perform functional study for the mutant protein, which is one limitation of our study.
In conclusion, we report the first Chinese patient with Mast syndrome carrying a large homozygous SPG21 deletion. Our study broadens the genetic and phenotypic spectrums of Mast syndrome.

ACK N OWLED G EM ENTS
We would like to thank the participants for their support and willingness to participate in this study.

CO N FLI C T O F I NTE R E S T
The authors have no competing interests to declare.

CO N S ENT TO PA RTI CI PATE
The patient provided written consent for participation. F I G U R E 1 A Chinese family with a large homozygous SPG21 deletion. (A) Pedigree tree of the family; (B) proband brain MRI at the age of 37: sagittal T2-weighted image (left) and axial T2 FLAIR image (right); (C) breakpoint detection of the large deletion of SPG21 by primerwalking PCR strategies. (D) Identification of the breakpoints by sequencing of the long-range PCR product